A Neutralizing Anti-gH/gL Monoclonal Antibody Is Protective in the Guinea Pig Model of Congenital CMV Infection

PLoS Pathogens

Volumn 10, Issue 4, 2014, Pages

  Auerbach, Marcy R ^a   Yan, Donghong ^a   Vij, Rajesh ^a   Hongo, Jo Anne ^a   Nakamura, Gerald ^a   Vernes, Jean Michel ^a   Meng, Y Gloria ^a   Lein, Samantha ^a   Chan, Pamela ^a   Ross, Jed ^a   Carano, Richard ^a   Deng, Rong ^a   Lewin Koh, Nicholas ^a   Xu, Min ^a   Feierbach, Becket ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; FC RECEPTOR; GLYCOPROTEIN H; GLYCOPROTEIN L; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACULOVIRUS; CONGENITAL INFECTION; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DNA ISOLATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FETUS WASTAGE; GENE DOSAGE; GUINEA PIG; HUMAN; HUMAN CELL; MALE; MATERNAL MORTALITY; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PREGNANCY; PROTEIN EXPRESSION; RECEPTOR BINDING; SEROCONVERSION; VIRUS GENOME; VIRUS NEUTRALIZATION; ANIMAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DISEASE MODEL; HEK293 CELL LINE; IMMUNOLOGY; PATHOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; GUINEA PIGS; HEK293 CELLS; HUMANS;

EID: 84901311908     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004060     Document Type: Article

References (41)

1. Bratcher DF, Bourne N, Bravo FJ, Schleiss MR, Slaoui M, et al. (1995) Effect of passive antibody on congenital cytomegalovirus infection in guinea pigs. J Infect Dis 172: 944-950.
2. Bourne N, Schleiss MR, Bravo FJ, Bernstein DI, (2001) Preconception immunization with a cytomegalovirus (CMV) glycoprotein vaccine improves pregnancy outcome in a guinea pig model of congenital CMV infection. J Infect Dis 183: 59-64.
3. Chatterjee A, Harrison CJ, Britt WJ, Bewtra C, (2001) Modification of maternal and congenital cytomegalovirus infection by anti-glycoprotein b antibody transfer in guinea pigs. J Infect Dis 183: 1547-1553.
4. Stagno S, Whitley RJ, (1985) Herpesvirus infections of pregnancy. Part I: Cytomegalovirus and Epstein-Barr virus infections. N Engl J Med 313: 1270-1274.
5. Rosenthal LS, Fowler KB, Boppana SB, Britt WJ, Pass RF, et al. (2009) Cytomegalovirus shedding and delayed sensorineural hearing loss: results from longitudinal follow-up of children with congenital infection. Pediatr Infect Dis J 28: 515-520.
6. Ross SA, Fowler KB, Ashrith G, Stagno S, Britt WJ, et al. (2006) Hearing loss in children with congenital cytomegalovirus infection born to mothers with preexisting immunity. J Pediatr 148: 332-336.
7. Alford CA, Stagno S, Pass RF, Britt WJ, (1990) Congenital and perinatal cytomegalovirus infections. Rev Infect Dis 12 (Suppl 7):: S745-753.
8. Fowler KB, Stagno S, Pass RF, (2003) Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 289: 1008-1011.
9. Lilleri D, Kabanova A, Lanzavecchia A, Gerna G, (2012) Antibodies against neutralization epitopes of human cytomegalovirus gH/gL/pUL128-130-131 complex and virus spreading may correlate with virus control in vivo. J Clin Immunol 32: 1324-1331.
10. Lilleri D, Kabanova A, Revello MG, Percivalle E, Sarasini A, et al. (2013) Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH/gL/pUL128-130-131 complex during primary infection. PLoS One 8: e59863.
11. Nigro G, Adler SP, La Torre R, Best AM, (2005) Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 353: 1350-1362.
12. Schleiss MR, (2002) Animal models of congenital cytomegalovirus infection: an overview of progress in the characterization of guinea pig cytomegalovirus (GPCMV). J Clin Virol 25 (Suppl 2):: S37-49.
13. Bakardjiev AI, Stacy BA, Fisher SJ, Portnoy DA, (2004) Listeriosis in the pregnant guinea pig: a model of vertical transmission. Infect Immun 72: 489-497.
14. Mess A, (2007) The Guinea pig placenta: model of placental growth dynamics. Placenta 28: 812-815.
15. Bia FJ, Griffith BP, Fong CK, Hsiung GD, (1983) Cytomegaloviral infections in the guinea pig: experimental models for human disease. Rev Infect Dis 5: 177-195.
16. Bia FJ, Summers WC, Fong CK, Hsiung GD, (1980) New endogenous herpesvirus of guinea pigs: biological and molecular characterization. J Virol 36: 245-253.
17. Bia FJ, Miller SA, Davidson KH, (1984) The guinea pig cytomegalovirus model of congenital human cytomegalovirus infection. Birth Defects Orig Artic Ser 20: 233-241.
18. Hsiung GD, Choi YC, Bia F, (1978) Cytomegalovirus infection in guinea pigs. I. Viremia during acute primary and chronic persistent infection. J Infect Dis 138: 191-196.
19. Paglino JC, Brady RC, Schleiss MR, (1999) Molecular characterization of the guinea-pig cytomegalovirus glycoprotein L gene. Arch Virol 144: 447-462.
20. Schleiss MR, (1994) Cloning and characterization of the guinea pig cytomegalovirus glycoprotein B gene. Virology 202: 173-185.
21. Brady RC, Schleiss MR, (1996) Identification and characterization of the guinea-pig cytomegalovirus glycoprotein H gene. Arch Virol 141: 2409-2424.
22. Nozawa N, Yamamoto Y, Fukui Y, Katano H, Tsutsui Y, et al. (2008) Identification of a 1.6 kb genome locus of guinea pig cytomegalovirus required for efficient viral growth in animals but not in cell culture. Virology 379: 45-54.
23. Auerbach M, Yan D, Fouts A, Xu M, Estevez A, et al. (2013) Characterization of the guinea pig CMV gH/gL/GP129/GP131/GP133 complex in infection and spread. Virology 441: 75-84.
24. Britt WJ, Harrison C, (1994) Identification of an abundant disulfide-linked complex of glycoproteins in the envelope of guinea pig cytomegalovirus. Virology 201: 294-302.
25. Schleiss MR, McGregor A, Choi KY, Date SV, Cui X, et al. (2008) Analysis of the nucleotide sequence of the guinea pig cytomegalovirus (GPCMV) genome. Virol J 5: 139.
26. Ober RJ, Radu CG, Ghetie V, Ward ES, (2001) Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol 13: 1551-1559.
27. Waldmann TA, Strober W, (1969) Metabolism of immunoglobulins. Prog Allergy 13: 1-110.
28. Bia FJ, Griffith BP, Tarsio M, Hsiung GD, (1980) Vaccination for the prevention of maternal and fetal infection with guinea pig cytomegalovirus. J Infect Dis 142: 732-738.
29. Griffith BP, Lavallee JT, Jennings TA, Hsiung GD, (1985) Transmission of maternal cytomegalovirus-specific immunity in the guinea pig. Clin Immunol Immunopathol 35: 169-181.
30. Macagno A, Bernasconi NL, Vanzetta F, Dander E, Sarasini A, et al. (2010) Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J Virol 84: 1005-1013.
31. Barrios Y, Knor S, Lantto J, Mach M, Ohlin M, (2007) Clonal repertoire diversification of a neutralizing cytomegalovirus glycoprotein B-specific antibody results in variants with diverse anti-viral properties. Mol Immunol 44: 680-690.
32. Maidji E, McDonagh S, Genbacev O, Tabata T, Pereira L, (2006) Maternal antibodies enhance or prevent cytomegalovirus infection in the placenta by neonatal Fc receptor-mediated transcytosis. Am J Pathol 168: 1210-1226.
33. Boeckh M, Bowden RA, Storer B, Chao NJ, Spielberger R, et al. (2001) Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 7: 343-351.
34. Borucki MJ, Spritzler J, Asmuth DM, Gnann J, Hirsch MS, et al. (2004) A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis. Antiviral Res 64: 103-111.
35. Manley K, Anderson J, Yang F, Szustakowski J, Oakeley EJ, et al. (2011) Human cytomegalovirus escapes a naturally occurring neutralizing antibody by incorporating it into assembling virions. Cell Host Microbe 10: 197-209.
36. Freed DC, Tang Q, Tang A, Li F, He X, et al. (2013) Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine. Proc Natl Acad Sci U S A 110: E4997-5005.
37. Hartley JW, Rowe WP, Huebner RJ, (1957) Serial propagation of the guinea pig salivary gland virus in tissue culture. Proc Soc Exp Biol Med 96: 281-285.
38. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
39. Szymczak AL, Workman CJ, Wang Y, Vignali KM, Dilioglou S, et al. (2004) Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol 22: 589-594.
40. Katano H, Sato Y, Tsutsui Y, Sata T, Maeda A, et al. (2007) Pathogenesis of cytomegalovirus-associated labyrinthitis in a guinea pig model. Microbes Infect 9: 183-191.
41. Williams DA, (1975) The analysis of binary responses from toxicological experiments involving reproduction and teratogenicity. Biometrics 31: 949-952.